The company achieved multiple positive milestones in 2025 including FDA alignment on accelerated approval pathway, positive Phase 2 results, strong enrollment momentum in Phase 3 trials, and adequate cash runway into mid-2027. Net loss decreased from $163.3M to $151.6M year-over-year, and the company is on track for pivotal data readout in Q2 2027, positioning it well for potential regulatory approval and commercialization.
Also mentions PROK
Articles that tag PROK but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
